ScrutarSign up free

Medline Inc. (MDLN)

SEC filings, insider trading & institutional ownership from EDGAR.

NasdaqIPO • Dec 2025Health CareHealth Care Equipment & Supplies

Medline Inc. is the largest provider of medical-surgical (med-surg) products and supply chain solutions serving all points of care, based on total net sales of med-surg products. Founded in 1966, the company states its mission as making healthcare run better by delivering improved clinical, financial and operational outcomes. It combines manufacturing, sourcing and distribution of med-surg products with supply chain services, supported by a Prime Vendor model, a distribution network and a commercial platform.

Medline has two reportable segments. The Medline Brand segment offers about 190,000 products under the Medline brand in three categories: Front Line Care (wound care, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, durable medical equipment and infection control products), Surgical Solutions (procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, gloves and orthopedic implants) and Laboratory and Diagnostics (point of care testing, analyzers, consumables, vital signs monitors, and pathology and phlebotomy products). The Supply Chain Solutions segment offers about 145,000 products from more than 1,300 third-party suppliers, including nearly all leading national brands. It also provides consulting, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization and route planning. Across both segments the company offers about 335,000 products. It holds more than 2,300 granted patents and more than 450 FDA 510(k) clearances, and has launched more than 250 new products in the last three years.

Customers range from hospitals and surgery centers to physician offices and post-acute facilities. Many are served through Prime Vendor relationships, which are multi-year agreements, typically five years, under which the customer buys the vast majority of its med-surg products from Medline. The company reports an average Prime Vendor retention rate above 98% over the past five years. A U.S. commercial team of about 4,000 people supports customers, with teams dedicated to each channel and each international region. No international market represents more than 3% of net sales.

Medline manufactures about one-third of its Medline Brand products, primarily Class I and II medical devices, in 30 manufacturing facilities, 24 of them in North America. It sources most of the rest from more than 600 partners in about 40 countries, with no single partner above 5% of spend. Its network has 70 distribution centers, warehouses, cross-docks and transship facilities, 45 in the United States, which provide next-day delivery to 95% of U.S. customers. It also runs more than 2,100 owned MedTrans trucks. Competitors include other med-surg manufacturers and distributors such as McKesson, Cardinal Health, Owens & Minor and Henry Schein. The company has over 45,000 employees, more than 26,000 in the United States, and is subject to extensive regulation, notably by the FDA.

AI-summarized from Item 1 (Business) of the company’s most recent 10-K filing.

RevenueFY2025
$28.43B
Net incomeFY2025
$1.16B
Diluted EPSFY2025
-$0.01
Gross margin
26.4%
Insider net6 mo
−960.8M
shares86 sells1 buys
Institutions
56
$14B held

Financials

As reported to the SEC via XBRL, no adjustments

All financials →
Revenue & net income
$10B$20B$30B
FY2025
RevenueNet income
FY2025 highlightsfrom 10-K
Gross profit$7.52B
Operating income$2.21B
Diluted EPS-$0.01
Gross margin26.4%
Net margin4.1%

Revenue by region

FY2025 geographic segments • from the 10-K

$28BTOTAL FY2025
Americas$26.48B93.1%—
Rest of World$1.95B6.9%—

Latest filings

10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR

All filings →
FormFiled
10-QNov 4, 2026
8-KNov 4, 2026
SC 13G/AamendedGIC Private Limited and 2 other reporting personsOct 30, 2026
8-KOct 21, 2026

Insider trading

From Form 4 filings

All →
InsiderDateType
Hux Investment Pte. Ltd.Oct 8, 2026Sell
GIC Special Investments Pte LtdOct 8, 2026Sell
GIC Private LtdOct 8, 2026Sell
Hux Investment Pte. Ltd.Oct 6, 2026Sell
Hux Investment Pte. Ltd.Oct 6, 2026Sell

Top holders

13F & 13D/G • latest quarter

All →
HolderStakeFiledValue
FMR LLC5.3%Aug 13, 2026$1.85B
Capital Research Global Investors4.5%Aug 12, 2026$1.58B
Invesco Ltd.4.4%Aug 14, 2026$1.51B
BlackRock, Inc.3.0%Aug 7, 2026$1.04B
MORGAN STANLEY2.5%Aug 13, 2026$852.13M

The IPO at a glance

From the final prospectus (424B4), filed Dec 18, 2025 • listed on Nasdaq Global Select Market as “MDLN”

Full offering read →
IPO price
$29.00
per Class A share
Sold by the company
216.0M
216,034,482 shares as printed
Net proceeds to the company
$6.13B
“approximately $6,129 million”
Share classes
Class A common stock • one voteClass B common stock • one vote
Lock-up
180 days
Led by
Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC

Figures are quoted from the prospectus as printed.

The full offering read is free with an account

What the money is for, the risk themes in the prospectus’s own terms, dilution to new investors, and the red-flag scan of the offering, verified against the filing.

Sign up free →

Executive pay and the vote

From the FY2025 proxy statement (DEF 14A), filed Apr 23, 2026, and the annual meeting’s vote on Jun 11, 2026

Full governance view →
CEO total pay
$3.9M
James M. Boyle • FY2025
Actually paid
$61.8M
SEC “compensation actually paid”
Say-on-pay
99.5%
of votes cast • 8-K filed Jun 12, 2026
TSR on $100
$102.44
peers $101.10 • since FY2025
What the company says drives pay
Plan Adjusted EBITDANet SalesAdjusted Gross Margin less Expense Year over Year Growth (Commercial)

Figures come from the company’s proxy statement, and the vote count from its 8-K.

The full pay and vote breakdown is free with an account

The Summary Compensation Table for every named officer, the board with tenure and committees, and each proposal with its count, verified against the filings.

Sign up free →
AI summary

Latest 10-Q takeaways

filed Nov 4, 2026

Management reports strong top-line growth (+10.4% net sales), lower interest expense and solid cash generation, but this is offset by a destructive distribution center fire, three unresolved FDA warning letters, a bed market exit and recall, tariff pressures, and gross margin compression. The tone is factual and mixed, with moderately confident mitigation and liquidity assertions, heavy risk disclosure, and a mostly backward-looking results discussion.

Written by Scrutar's AI from MDLN's SEC filings. Check anything you rely on against the filing. Not investment advice.

MDLN's filings are public. The insight is one click away.

Scrutar's AI reads every MDLN filing and points out what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.

Analyze MDLN filingsNo credit cardAI reports included on the free plan

Never miss a MDLN filing.

Get an email when MDLN files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.

Free foreverNo account requiredOne-click unsubscribe

Protected by reCAPTCHA. Privacy & Terms

Companies related to MDLN

Peers identified from MDLN's own SEC filings.

Data as of Nov 9, 2026Source: SEC EDGAR.